Andrew Huberman· PhD
and rapamycin um also kind of reduces Emptor activation and people have shown that rapamycin and Metformin can extend Mouse lifespan and in improve health
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
and rapamycin um also kind of reduces Emptor activation and people have shown that rapamycin and Metformin can extend Mouse lifespan and in improve health
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
His most recent work was on the ability of rapamyin to delay cellular senecence and slow aging , and he was an advocate of taking rapamycin...
mTOR drives cell growth and metabolism—crucial for development early in life. Later, overactive mTOR can accelerate tissue damage. Rapamycin, by dialing down mTOR, extends lifespan in yeast, worms, flies, and mice—and is being explored in humans.
I have studied this protein that I'm glad you like a lot. It's my favorite protein called the mTOR protein, which is the protein through which this drug, rapamycin, which gets quite a bit of attention now, acts.
I don't think there's any reason to believe that I think it's just hey are we seeing yeah we're not seeing lifespan get shorter we're not seeing an uptick in cancer or something that was unanticipated
I think we all believe that rapy and inhibiting mtor slows biological aging at least in up to mice hopefully in dogs hopefully in people yeah so it's a fundamental node in the network that's the way I think about the Hallmarks of Aging it's a node in the network that underlies the Hallmarks of Aging so we can manipulate mtor with Ramy slow aging ramy's a pretty good anti-cancer drug until the cancers have evolved to ignore the mtor break and then rapy doesn't work anymore and we know ramyon doesn't work for most cancers that's an example tested we know this yeah absolutely
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.